KORU Medical Systems, Inc. (KRMD)
NASDAQ: KRMD · Real-Time Price · USD
3.700
+0.010 (0.27%)
At close: Nov 13, 2026, 4:00 PM EST
3.700
0.00 (0.00%)
Pre-market: Nov 16, 2026, 7:53 AM EST
← View all transcripts

Canaccord Genuity's MedTech, Diagnostics and Digital Health & Services Forum

Nov 11, 2026

Summary

Q3 growth was 11%, with a second consecutive EBITDA-positive quarter and FY revenue guidance raised to $48 million–$48.5 million. International expansion, RYSTIGGO uptake and Freedom360 development support the growth outlook, with profitability expected next year.

Caitlin Roberts
Director of MedTech Equity Research, Canaccord Genuity MedTech

Good morning, everyone, and thank you for joining us at this year's Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum. My name is Caitlin Roberts, and I'm one of the medical device analysts here at Canaccord. I'm pleased to be joined this morning by KORU Medical, a medical device company focused on innovative portable solutions for the drug delivery market. With me today is Adam Kalbermatten, CEO, and Tom Adams, CFO. Before we begin, I want to remind everyone of any relevant disclosures, which can be found in our conference and our firm website. We'll begin with a Q&A, a fireside chat with the KORU team, and I'll try to leave a couple minutes at the end for any questions from the audience. Maybe we can get started with the Q3, since you just reported results last night.

Bit of a noisy quarter from a comp perspective, but maybe just speak to how the business performed versus your expectations and what gives you confidence in achieving the guidance for this year.

Adam Kalbermatten
CEO, KORU Medical

Absolutely. Good morning, everybody. Maybe a quick background before I dig into the specific question on KORU and who we are. KORU Medical is a company focused on large volume subcutaneous drug delivery. Over 90% of our business is supporting immunoglobulin patients who have to self-administer medications on a weekly and monthly basis. We just reported earnings for our third quarter yesterday. To Caitlin's question, we just came out of a pretty solid quarter that we had for Q3. In that quarter, not only we deliver strong growth for the year, we had 11% growth on the quarter, but we had our second consecutive quarter of EBITDA positive earnings. So we were very impressed with our results. Outside of that, we had a few instrumental things that we hinted at in our previous quarter that we were continuing to execute our expansion internationally.

We'll get into that a little bit later, but we did sign some new agreements, and we were able to overcome some of those challenges that we were thinking about that we really needed to make a progress on, so that as we got to Q4, we set ourselves up for a solid close to the year.

Caitlin Roberts
Director of MedTech Equity Research, Canaccord Genuity MedTech

Great. Adam, you joined as CEO recently. Maybe just as you settle further into the role, talk about how you are seeing the business and maybe your vision going forward.

Adam Kalbermatten
CEO, KORU Medical

Yeah, absolutely. When I joined KORU, I joined about a year and a half ago, and joined the company coming from the last 20 years in drug delivery. A lot of the work that I had previously done was kind of at the convergence of med tech and pharmaceutical companies, supporting pharmaceutical companies with the administration of their drug assets. Coming to KORU and having 510(k) marketed and approved products for the delivery of immunoglobulin therapies is a great basis for us as we look at kind of the larger shifts in pharmaceuticals that are continuing to move to subcutaneous delivery, but also shifting care out of hospitals, out of infusion centers, and into the home. For me, that was a great basis to continue to build on.

At KORU, what we are now focused on is not only growing within our core, both domestically and internationally with immunoglobulin patients, but also bringing additional therapies on label, which span into other rare disease indications, potentially oncology, and other areas where pharmaceutical companies are looking to enable patients to self-administer their medications.

Caitlin Roberts
Director of MedTech Equity Research, Canaccord Genuity MedTech

Great. I understand it is not yet 2027, but if you could provide investors some framework of how to start thinking about next year and maybe the cadence of the top and the bottom lines.

Adam Kalbermatten
CEO, KORU Medical

Absolutely. So we're not specifically guiding on where we're going to be in 2027 financially, but we do have a lot of core elements of our strategy that are continuing to progress. So domestically, we continue to outpace the market with our growth. The market's growing 8%-10% a year. We're growing a bit above that in the mid-teens. We've been doing that kind of year-on-year the past few years. Internationally, we continue to expand above market growth rates as well. We're entering new countries and continuing to sign new sales and distribution agreements across the board. That's what I referred to a little bit earlier of what we executed in the third quarter here.

We look at that providing a lot of the basis for us to continue to grow as not only the fourth quarter comes, but as we look into 2027 and we're capturing those new patient starts. We're also really excited. We have a new product that we've been developing for the past few years called our Freedom360. It's a product that's focused on satisfying some of the unmet needs patients have, specifically around end-of-dose notifications and having administrations that require multiple prefilled syringe formats so that they could more easily interchange the formats and reduce their overall administration time. So we're really excited about what's coming in 2027. We have a number of pipeline programs with pharmaceutical partners that continues to expand and make progress. We highlighted some of those yesterday.

A lot of really good, exciting things to think about that are going to translate into revenue over the next 12 to 18 months.

Caitlin Roberts
Director of MedTech Equity Research, Canaccord Genuity MedTech

Great. You had this year, in addition to your core business with RYSTIGGO, and on the Q3 call, you talked about three spec pharmas now dispensing RYSTIGGO. Maybe speak to the contribution that the product is making to core revenues and where that can go from here.

Adam Kalbermatten
CEO, KORU Medical

Absolutely. In Q3, as Caitlin just mentioned, we had three specialty pharmacies that completed their clinical evaluations and selected the KORU system for the administration of UCB's RYSTIGGO drug. This is an exciting one because it is a drug outside of immunoglobulin therapy, and it is kind of a proof point of us shifting into other further therapeutic areas. These three specialty pharmacies administer the drug to patients both in ambulatory infusion clinics, but also sending nurses into the home environment to support patients with the self-administration or healthcare worker-facilitated administration. We see it as a nice contributor to our growth as we pick up new patient starts. The drug is in the kind of early stages of its growth phase, so we see that ramping to a potential of $1 million in total revenue over the next few years.

It is a solid addition to our platform, and we look forward to serving those patients as it continues to grow.

Caitlin Roberts
Director of MedTech Equity Research, Canaccord Genuity MedTech

Great. Turning to international, it continues to be an important opportunity for you guys, and you noted progress this quarter on non-tender markets in Europe. Maybe provide an explanation of tender versus non-tender markets and why the go-to-market strategy differs between those.

Adam Kalbermatten
CEO, KORU Medical

Absolutely. This is an interesting one that when we are operating in markets outside of the U.S., specifically in Europe, you have two types of healthcare systems when it comes to immunoglobulin therapy. The first is a tender market. In those tender markets, you are typically having a pharmaceutical company that is putting in different types of bids to win business in certain geographies. In those tender markets, those pharmaceutical companies also have to provide a drug delivery device as part of that tender. You are essentially working in collaboration with the pharmaceutical company to help them win that tender and then serve their patients. There are some markets where KORU has had success in the past. Last year, notably, there was a major market that one of our pharmaceutical partners won the tender, and we essentially flipped that market over the course of the last 12 to 18 months.

The other type of market that exists would be a competitive market, where it is traditionally a company like KORU going out and working with pharmacies and home care companies or drug wholesalers and trying to say, "Hey, we have the products that can help patients administer the drugs that they need to take." Those are competitive markets where you are working with distributors and local sales organizations in each of the different geographies to win on an account-by-account basis. KORU operates in both of these worlds, but it is important to note some of the differences because the new patient starts could be either much more chunky and taking over a geography all at once, where tenders are won, or it could be on an account-by-account basis, where you are working with a distribution arm and each of the different accounts that help provide products to the patients.

Caitlin Roberts
Director of MedTech Equity Research, Canaccord Genuity MedTech

Great. You also announced this quarter the signing of two agreements, one in Europe and one in Africa. Maybe just talk to why you signed those agreements and when we can expect revenue contribution from them.

Adam Kalbermatten
CEO, KORU Medical

Absolutely. We are really excited with some of that groundwork we laid this quarter in signing these two agreements. The first was with a pan-European partner that operates both a drug wholesaler, a pharmacy, and a home care arm of their business. Why were we excited to work with them? Because now, as the drugs are being distributed and prescribed and the patients are being trained specifically by the home care companies, we have a direct access in as the device provider who can help also support those patients. We look at it as a way that as we bring our products out there, we can ease the administration for the patients, really remove some of the burdens with the current standard of care, and help provide that streamlined service now. That is the one agreement we signed in Europe.

The other one was actually a geographic expansion where we really did not have a partner before in Africa. This is a way that we look at our product as being able to serve patients that really did not have access to the devices to administer their immunoglobulin therapies in the past, and we are really excited about what is out there. We think there could even be some opportunities beyond immunoglobulin. This one is more of an upside opportunity that we are exploring, and we are pretty excited about some of the things that we hope we are going to find. We at least know we are going to have our continued international expansion in immunoglobulin therapies into Africa, but continuing to look at some other adjacencies there. We are pretty excited about what else could exist there.

Caitlin Roberts
Director of MedTech Equity Research, Canaccord Genuity MedTech

Great. There are some puts and takes to the cadence of the growth, OUS, with distributors and partnerships, but what do you view as your longer-term international growth expectations?

Adam Kalbermatten
CEO, KORU Medical

Great question. When we think about international today, we are somewhere around probably a 20% market share. So, there is a lot of untapped potential for us to continue to expand. That is going to be both in tender markets and also in competitive markets. So, as we think about it in the longer term, we think we are going to keep increasing our market share with those new patient starts.

The nature of our business is recurring revenue in general, so as you pick up a patient, you typically have those patients for the duration of their therapies, as long as you continue to support things with that patient and there are not any challenges that arise. So, as we think about it, each one of those patients and new patient starts is what we focus on. That way, we continue to support them for the life of their therapy.

We would love to see that market share continue to grow. I will not speculate on how far we think we can get it, but in the U.S., we see our market share as upwards of 60%, 70%, if not higher, being a little bit conservative there, but we hope that we could get to the same type of share position in international markets as well.

Caitlin Roberts
Director of MedTech Equity Research, Canaccord Genuity MedTech

Great. Just turning to the pipeline, you noted a few updates on your opportunities this quarter. What were those updates, and what do you view as the nearest-term opportunities in the pipeline?

Adam Kalbermatten
CEO, KORU Medical

Absolutely. We touched on two specific existing pipeline updates this past quarter where our pharmaceutical partners continued to make progress with drug assets that they had in their development pipelines. The first was an enzyme replacement therapy where they continued advancing their phase III clinical trial, and they were dosing patients with the KORU Freedom Infusion System this quarter. Looking ahead a little bit, we anticipate that it is going to take another one to two years for them to get through their clinical trial and all of the regulatory approvals required, but hopefully towards the end of 2028, 2029 is when we would see that current therapy coming to market.

It is one of those elements that is really not under our direct control because it is our partner's asset being developed, but we are right there and ready to support their patients as soon as they gain approval, and we look forward to helping them be successful in their clinical trials. The other one is a nephrology asset that is in a phase II/III clinical study. It is just starting its phase III study coming up. We actually executed an additional statement of work with them to support their international expansion. That one is a little bit earlier as it is just starting its phase III trials, and if they are successful, we expect that those patients would be able to start receiving commercial treatments probably in the 2030, 2031 timeframe.

These are long-term developments that our pharmaceutical partners are focused on, and we look at them as ways for us to continue adding value to new patient populations and new therapeutic areas. We are pretty excited about the potential to help get these medicines to market.

Caitlin Roberts
Director of MedTech Equity Research, Canaccord Genuity MedTech

Okay. Oncology continues to be a major focus, but you recently decided to pursue a different initial entry point into the U.S. market than you originally anticipated. Could you give the audience some color on the developments here and also on what the revised pathway looks like?

Adam Kalbermatten
CEO, KORU Medical

Yeah, absolutely. We're not commenting on detail on our oncology footprint at the moment, but I'll give you guys a little bit of a preview in terms of where we are and where we've come from. We look at a lot of the oncology treatments that are administered in infusion centers today. A lot of them have shifted from IV to subcu administration. And with that, the nurses and the healthcare workers are typically having to stand chairside by a patient for anywhere from five to 15 minutes, just manually pushing with a syringe. We think about it as we have solutions that can help with that. We had gone through a bit of a first attempt to make it into the market in oncology, specifically for a drug called PHESGO.

There were some things as we were working with our pharmaceutical partner that they didn't want to pursue label updates, and that was unfortunately something outside of our control that we weren't able to make that our initial entry into oncology. We do have another molecule right now we're working with a partner on. It's something that we see it as a much stronger entry into oncology. I'll kind of leave it at that at the moment because it's not really something that we're sharing at the moment, based upon our customer and their desire to keep the information for the moment. But we are really excited about it, and we are planning to share additional details kind of on our path forward as we get into the first half of 2027.

Caitlin Roberts
Director of MedTech Equity Research, Canaccord Genuity MedTech

And oncology is another infusion clinic-type opportunity. Maybe speak to any learnings from the early RYSTIGGO launch and if you see any parallels there.

Adam Kalbermatten
CEO, KORU Medical

Yeah. We really like the RYSTIGGO opportunity as it diversified us into new therapeutic areas outside of IG, where we've largely been in the past. It's actually our second molecule that we've helped pharmaceutical companies in administering patients for, the other being Biogen Aspaveli and EMPAVELI molecule. But in RYSTIGGO, what was important this quarter is we actually had the clinical buy-in from three specialty pharmacies that are administering RYSTIGGO directly in infusion centers. These are in ambulatory infusion centers as opposed to oncology infusion centers, but they operate in a similar way where a patient comes into an infusion center and they're administered with the drug using the KORU product. So we very much see oncology in a similar parallel to that. The other part of RYSTIGGO that is exciting for us is it's also administered by a healthcare worker in the home.

So if a patient doesn't want to come to a clinic, they may have a healthcare worker that comes to them in the home and administers RYSTIGGO using the KORU products. We see that as something for oncology is not only in infusion clinics today, but because we are able to help support dosing patients at home, that could be a potential if oncology ever moves into the home in the future.

Caitlin Roberts
Director of MedTech Equity Research, Canaccord Genuity MedTech

Okay. Then maybe just turning to new products. Adam, you touched on the next generation of the Freedom Platform earlier. Maybe just walk us through the timeline for that and what are the big updates to the platform?

Adam Kalbermatten
CEO, KORU Medical

Absolutely. So today we have two pumps that operate out there in the market with 510(k) and MDR approvals. So it's our KORU Freedom Infusion System, our FreedomEDGE Pump for lower volumes, and then our Freedom60 Platform for larger volumes. We have a new Freedom360 Pump that we're going to be We finished the design verification and all the product development work, and we're going to be applying for 510(k) approval later this year. So, we've got about a month left, and we're putting the final touches on that regulatory filing. This is a pump that's going to be a nice complement to our portfolio, and specifically for those patients that are now using prefilled syringes, they're going to be able to use multiple different syringes in this pump.

They're not going to need to do manual transfers of drugs from vials into syringes of multiple formats to make it compatible with the pump. The pump is now compatible with all of those different syringe formats directly. So, we look at this as a nice value add, bringing more value to patients, and really excited about when we could bring this out there to market, and gotten very positive feedback so far on the product development side. So now we're looking to enter the clinical evaluations. Very much how we did that when we brought RYSTIGGO on label, we'll be doing the same thing with a number of the immunoglobulin therapies as we look into 2027 and have that approval.

Caitlin Roberts
Director of MedTech Equity Research, Canaccord Genuity MedTech

Great. How are you thinking about the potential launch of that internationally as well?

Adam Kalbermatten
CEO, KORU Medical

Yeah. The international market will be a follow-on for us. We don't have specific timing on it yet because we're very, very focused on the U.S. market launch. Internationally, we're gaining a lot of traction with our existing products, so it's something that as we see the continued expansion of prefilled syringes and other products internationally, we would expect that we'll have opportunities to follow on with bringing that Freedom360 out internationally compared to just in the U.S.

Caitlin Roberts
Director of MedTech Equity Research, Canaccord Genuity MedTech

Great. Maybe Tom, I'll give you some airtime with some finance questions. As you went through a number of efforts to make the business more operationally efficient and cash efficient, how are you thinking about managing growth and cash needs versus cash generation?

Tom Adams
CFO, KORU Medical

Yeah. Thanks, Caitlin. We're really excited. We hit two quarters in a row of profitability. We're starting to generate cash, right? We expect to have an immaterial burden this year of less than $1 million. As we think about next year and beyond, as you know, our growth is to get to $100 million, double in size over the next three years. We've invested in operational efficiencies to improve our gross margin up to about 65%, which we anticipate to hold. We'll be choiceful with our investments. We're profitable. We will be profitable next year, and we want to ensure that what we invest in supports our $100 million efforts, right, as we move forward over the next three years.

We will be choiceful on R&D spend, we will be choiceful on marketing and sales spend, and we will make sure there is some nice returns on those investments.

Caitlin Roberts
Director of MedTech Equity Research, Canaccord Genuity MedTech

As more opportunities come off of the pipeline and then into the core revenues, how are you thinking about spending there going forward?

Tom Adams
CFO, KORU Medical

Yeah. I mean, as you know, our model, Caitlin, is a 510(k) model. We work with our partners, and we will continue to be a delivery service for them, and we will work with them, and we will invest where we need based on our customers' needs, right, for their pipelines. There is a lot of subcutaneous drugs in phase I and phase II out there. We are constantly having these conversations with them and making decisions on what we are going to invest as they bring their products to market.

Caitlin Roberts
Director of MedTech Equity Research, Canaccord Genuity MedTech

Great. Any questions from the audience? Okay. Well, would love if you guys could just leave us with about a minute or so of your thoughts on the quarter and where KORU Medical is going forward.

Adam Kalbermatten
CEO, KORU Medical

Absolutely. Not to reiterate everything we have gone through, but as we finish the third quarter, we have gone through what we consider a lot of the building for the next steps of our revenue build going into Q4 and into 2027. We have executed on our strategy both domestically and internationally, and continuing to advance pipeline products moving forward. We also look at it as we have a very strong quality business that is kind of sitting underneath all of the financial delivery. We have about 60,000 patients now that are continuing to use the KORU Freedom Infusion System on a recurring basis to treat themselves. That creates a recurring revenue base from us that, as we continue to add new patient starts, we just continue to take on additional opportunities to build value and reinvest in the business. We are looking forward to finishing up this year.

We raised the bottom end of our guidance, so we should be somewhere between $48 million-$48.5 million in overall revenues. As we are approaching that $50 million part, it is kind of an inflection point where we see that the kind of cash that the business is going to continue to kick off that we can invest is going to really start to accelerate. We are really excited about what is to come, and for those of you who have been following the story, I think you will see we have been executing really well. For anybody who is new to our story, would love to sit down and walk you through the details. But we are really excited about what the future has here. This is a pretty exciting journey that we are on.

Caitlin Roberts
Director of MedTech Equity Research, Canaccord Genuity MedTech

Thank you both.

Adam Kalbermatten
CEO, KORU Medical

Thanks, Caitlin.